Helius Medical Technologies Inc (OTCMKTS:HSDT)’s share price gapped up prior to trading on Friday . The stock had previously closed at $1.39, but opened at $1.26. Helius Medical Technologies shares last traded at $1.18, with a volume of 293,688 shares.
Separately, Zacks Investment Research upgraded shares of Helius Medical Technologies from a “sell” rating to a “hold” rating in a research note on Wednesday.
The company’s 50 day moving average is $0.74 and its 200 day moving average is $1.48.
Helius Medical Technologies (OTCMKTS:HSDT) last released its earnings results on Tuesday, November 12th. The company reported ($0.22) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.22). The company had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.30 million.
Large investors have recently added to or reduced their stakes in the stock. Morgan Stanley increased its holdings in Helius Medical Technologies by 302.7% in the 2nd quarter. Morgan Stanley now owns 14,072 shares of the company’s stock valued at $31,000 after buying an additional 10,578 shares during the period. A.R.T. Advisors LLC bought a new stake in Helius Medical Technologies in the 2nd quarter valued at $35,000. Bank of Montreal Can increased its holdings in Helius Medical Technologies by 6,777.4% in the 2nd quarter. Bank of Montreal Can now owns 20,701 shares of the company’s stock valued at $45,000 after buying an additional 20,400 shares during the period. Paloma Partners Management Co bought a new stake in Helius Medical Technologies in the 2nd quarter valued at $177,000. Finally, Millennium Management LLC increased its holdings in Helius Medical Technologies by 627.9% in the 3rd quarter. Millennium Management LLC now owns 207,895 shares of the company’s stock valued at $343,000 after buying an additional 179,336 shares during the period.
Helius Medical Technologies Company Profile (OTCMKTS:HSDT)
Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device.
Read More: What is a stock buyback?
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.